Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Abbott Laboratories    ABT   US0028241000

Delayed Quote. Delayed Nyse - 10/22 04:00:32 pm
41.59 USD   -1.89%
4h agoDJHealth Care Down as Biogen, Intuitive Surgical Weigh -- Health Care Roun..
11h agoDJU.S. HOT STOCKS : Hot Stocks to Watch
12h ago ABBOTT LABORATORIES : tops 3Q profit expectations
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

Abbott Laboratories : Abbott Receives U.S. FDA Clearance to Use iFS Advanced Femtosecond Laser Technology for Arcuate Incisions in Cataract Surgery

04/20/2012 | 09:05am US/Eastern

ABBOTT PARK, Ill., April 20, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) announced today U.S. Food and Drug Administration clearance to use its iFS Advanced Femtosecond Laser to create bow-shaped or curved arcuate incisions in corneal surgery, including cataract surgery.

The iFS Laser is currently used to create LASIK flaps and other corneal incisions in the eye and is the fifth generation of IntraLase technology, which has been used in more than 5 million procedures worldwide.

Nearly 3 million patients undergo cataract surgery each year in the United States. With this new clearance, the iFS Laser now gives surgeons the ability to make precise, bladeless arcuate incisions during surgery and customize the incision for each individual patient.

Factors such as placement, length, depth and radius of curvature can influence the surgeon's desired change to the cornea. These parameters can be difficult to control through traditional incisions made by hand using surgical knives. Now, using the iFS Laser, arcuate incisions can be performed with greater precision, predictability and customization than is possible with a manual technique.

"This is a major advancement and expansion of our Femtosecond laser technology," said Jim Mazzo, senior vice president, Abbott Medical Optics. "Abbott has been a pioneer in the ophthalmic use of Femtosecond lasers, and this new use of our technology demonstrates our leadership position in this very dynamic and competitive market. This is an important step as we look to utilize Femtosecond laser technology as a potential standard of care during the cataract procedure."

Study data support that the iFS Femtosecond laser creates arcuate incisions safely and effectively as prescribed by the physician, and complies with applicable safety standards.

This new use of Abbott's iFS Femtosecond laser is available now in the United States.

About Abbott Medical Optics (AMO)

Abbott Medical Optics is focused on delivering life-improving vision technologies to people of all ages. The company offers a comprehensive portfolio of cataract, refractive and eye care products. Products in the cataract line include monofocal and multifocal intraocular lenses (IOLs), phacoemulsification systems, viscoelastics, and related products used in ocular surgery. Products in the refractive line include wavefront diagnostic devices, femtosecond lasers and associated patient interface devices; excimer laser vision correction systems and treatment cards. Products in the eye care line include disinfecting solutions, enzymatic cleaners, lens rewetting drops and artificial tears.

For more information, please visit www.abbottmedicaloptics.com.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 91,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at www.abbott.com.

SOURCE Abbott

Latest news on ABBOTT LABORATORIES
4h agoDJHealth Care Down as Biogen, Intuitive Surgical Weigh -- Health Care Roundup
5h ago ABBOTT LABORATORIES : "Nutritional Compositions Comprising a Soluble Viscous Fib..
11h agoDJU.S. HOT STOCKS : Hot Stocks to Watch
11h ago ABBOTT LABORATORIES : Results of Operations and Financial Condition, Financial S..
12h ago ABBOTT LABORATORIES : tops 3Q profit expectations
13h ago ABBOTT LABORATORIES : Entry into a Material Definitive Agreement (form 8-K)
13h ago ABBOTT LABORATORIES : Assigned Patent
1d ago AbbVie CEO Gonzalez loses Shire, but wins praise for gutsy move
1d ago AbbVie CEO Gonzalez loses Shire, but wins praise for gutsy move
2d ago AbbVie says $55 billion acquisition of Shire officially dead
Dynamic quotes  
ON
| OFF